Please see the end of the video for
important safety information,
including boxed warning, and visit
XEOMIN.com for full prescribing
information.
Hello, my name's Warner Carr.
I'm a allergist and clinical
immunologist.
It is my pleasure today to talk to
you about immunogenicity associated
with botulinum type
A toxins for the treatment of
movement disorders.
Neutralizing antibodies are
antibodies that your body makes and
they're targeted against a pathogen
or a toxin or something that
your body sees as a foreign invader.
And what they do is they neutralize
the function of that foreign
invader. Formation of
neutralizing antibodies can
lead to clinical resistance.
If the patient is developing a
neutralizing antibody against the
therapy, you're going to see issues.
You're going to see a decrease in
effectiveness. You're going to see a
dose creep.
The patient's going to have to come
back into the doctor's office more
frequently.
In patients that have these movement
disorders, they're
going to be on these biological
therapies for the long term.
So it's very important, especially
in the young patient, the
teenagers and the adolescents, to
choose something that
has a very low potential for
the generation of a neutralizing
antibody. A higher protein
load increases
your risk of developing
an antibody,
and developing in particular a
neutralizing antibody.
The immunogenicity
of these biological products are
very, very important.
So much so that the FDA has
a guidance document for
any company that is developing
these biological therapies.
When choosing a therapy,
especially when you're treating
patients with movement disorders,
it's very important to
think about immunogenicity.
It's important to choose a
product that has a very low protein
load.
Xeomin is just
the biologically active 150
Kilo-Dalton Toxin.
And if you look at the clinical
trials that were conducted to
support the approval of XEOMIN,
you'll see it's a very low incidence
of production of neutralizing
antibodies.
And in addition to that, in
those patients, and in the adult
population, there was only 9.
And in the adolescent population,
there was only 4.
In those patients, there was no
signs of clinical resistance.
It's really my pleasure today to
talk to you guys about
immunogenicity and the importance
of immunogenicity in
treating patients with botulinum
type A toxin that have movement
disorders.